Event info
Date:27 Jan
Time:11:45-16:15
Venue:Oslo Cancer Cluster Innovation Park
Contact person
Nicole Mastrell

Nicole Mastrell

Event Manager & PA to CEO

nm@mva.org

+45 6141 8634

Cancer Crosslinks 2022

Getting Ahead of Tumor Evolution – ​Changing the Premises in the War Against Cancer

Join distinguished speakers from the UK, USA, Germany, Switzerland, Canada, and Norway as they discuss recent progress in the understanding of tumor evolution and emerging diagnostic and treatment options for solid and hematological cancers.

Cancer Crosslinks 2022 will be A Digital/Hybird Event streamed from Oslo Cancer Cluster Innovation Park. There is an option to attend on-site pending COVID-19 guidelines. For more information about registration and to join digitally and/or on-site, please visit the REGISTER HERE tab above.

Date: Thursday, January 27, 2022
Time: 11:45-16:15 CET
Venue: Digital/Hybird Event streamed from Oslo Cancer Cluster Innovation Park

 

READ MORE & SIGN UP

 

Cancer Crosslinks is an educational meeting series which promotes interactions between researchers and clinicians, and encourages translational and clinical research to support collaborations to advance the development of innovative cancer treatments.

​Established in 2009 by Oslo Cancer Cluster in collaboration with its member, Bristol Myers Squibb, this yearly meeting has become a leading forum gathering oncologists, hematologists, translational researchers, healthcare providers, regulatory experts, and industry representatives.

The hallmark of Cancer Crosslinks is the educational program featuring international and Norwegian experts presenting recent advances in oncology. The educational program is complemented by tailored activities to stimulate additional interactions and discussions between speakers and representatives from the oncology community.

WHY ATTEND CANCER CROSSLINKS?​

  • JOIN a growing community of oncologists and hematologists addressing progress  and emerging concepts in cancer treatment.
  • LEARN about recent progress in cancer diagnostics and treatments.
  • CONNECT ​with translational researchers and clinicians from academic centers.
  • NETWORK with international experts and expand opportunities to collaborate.